The expanding role of nilotinib in chronic myeloid leukemia

Bibliography

• Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370(9584):342-50
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561-6
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-51
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28-37
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349(15):1423-32
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23(6):1054-61
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358-63
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8(11):1018-29
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110(7):2242-9
   PubMed Web of Science ®Google Scholar
• Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21(8):1637-47
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7(5):345-56
   PubMed Web of Science ®Google Scholar
• Manley PW, Breitenstein W, Bruggen J, Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg Med Chem Lett 2004;14(23):5793-7
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-41
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500-5
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94(12):1765-9
   PubMed Web of Science ®Google Scholar
• Kagan M, Tran P, Fischer V, Safety, pharmacokinetics (PK), metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects. Blood 2005;106: Abstract 4887
   Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354(24):2542-51
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQ, Sethuraman V, Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010;87(2):197-203
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540-6
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. ASH Annu Meeting Abstracts 2009;114(22):1129
   Google Scholar
• Kantarjian HM, Giles F, Bhalla KN, Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. ASH Annu Meeting Abstracts 2008;112(11):3238
   Google Scholar
• Hochhaus A, Giles F, Apperley J, Nilotinib in chronic myeloid leukemia in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study. Haematologica 2009;94(Suppl. 2): abstract 0631
   PubMedGoogle Scholar
• le Coutre P, Ottmann OG, Giles F, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111(4):1834-9
   PubMed Web of Science ®Google Scholar
• Giles FJ, Larson RA, Kantarjian HM, Nilotinib in chronic myelogenous leukemia in blast crisis (CML-BC) patients with imatinib-resistance or -intolerance: updated phase 2 results. Haematologica 2008;93(Suppl. 1): abstract 0117
   Google Scholar
• Hazarika M, Jiang X, Liu Q, Tasigna for chronic and accelerated phase Philadelphia chromosome – positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008;14(17):5325-31
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28(3):392-7
   PubMed Web of Science ®Google Scholar
• O'Dwyer MC, Kent E, Parker M, Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 phase 2 study. ASH Annu Meeting Abstracts 2009 2009;114(22):3294
   Google Scholar
• Rosti G, Palandri F, Castagnetti F, Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009;114(24):4933-8
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251-9
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009;15(24):7519-27
   PubMed Web of Science ®Google Scholar
• Redaelli S, Piazza R, Rostagno R, Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(3):469-71
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O'Hare T, Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108(7):2332-8
   PubMed Web of Science ®Google Scholar
• Ray A, Cowan-Jacob SW, Manley PW, Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109(11):5011-15
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Manley PW, Mestan J, Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108(4):1328-33
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S, Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27(25):4204-10
   PubMed Web of Science ®Google Scholar
• Branford S, Kim D-W, Soverini S, Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP). ASH Annu Meeting Abstracts 2009;114(22):3292
   Google Scholar
• Laneuville P, Dilea C, Yin OQ, Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol 2010;28(11):e169-71
   PubMed Web of Science ®Google Scholar
• Kim TD, Turkmen S, Schwarz M, Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 2009;95(4):582-8
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111(8):4022-8
   PubMed Web of Science ®Google Scholar
• Singer JB, Shou Y, Giles F, UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21(11):2311-15
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6(4):219-28
   PubMed Web of Science ®Google Scholar
• Kim TD, Schwarz M, Nogai H, Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010 [Epub ahead of print]
   Google Scholar
• Nicolini FE, Kim D-W, Ceglarek B, Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or – intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (expanding nilotinib access in clinical trials) study. ASH Annu Meeting Abstracts 2009;114(22):2201
   Google Scholar
• le Coutre PD, Ceglarek B, Turkina A, Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the ENACT (expanding nilotinib access in clinical trials) study. ASH Annu Meeting Abstracts 2009;114(22):1115
   Google Scholar
• Koren-Michowitz M, le Coutre P, Duyster J, Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer 2010;116(19):4564-72
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Baccarani M, Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). ASH Annu Meeting Abstracts 2008;112(11):3215
   Google Scholar
• Hochhaus A, Baccarani M, Deininger M, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22(6):1200-6
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’. Leuk Lymphoma 2010;51(4):589-91
   Google Scholar
• Jabbour E, Hochhaus A, Cortes J, Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010;24(1):6-12
   PubMed Web of Science ®Google Scholar
• Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009;114(27):5426-35
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian H, Fava C, Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 2010;150(3):303-12
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):3204-12
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6(10):834-48
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11(1):12-9
   PubMed Web of Science ®Google Scholar